Today: 11 April 2026
Subscribe
Browse Category

NYSE:PFE 30 November 2025 - 15 December 2025

Pfizer Stock (PFE) News Today: Dividend, 2026 Guidance Call, Obesity Deals, and Analyst Forecasts (Dec. 15, 2025)

Pfizer Stock (PFE) News Today: Dividend, 2026 Guidance Call, Obesity Deals, and Analyst Forecasts (Dec. 15, 2025)

Pfizer shares traded at $25.85 as of 12:08 UTC Monday, unchanged from Friday’s close. The company will hold a conference call Tuesday morning to provide full-year 2026 financial guidance. Pfizer’s board declared a $0.43 first-quarter 2026 dividend, marking its 349th consecutive quarterly payout. Market cap stands near $147 billion.
15 December 2025
····
Pfizer Stock (PFE) Before Market Open Dec. 15, 2025: Key News, 2026 Guidance Call, Analyst Targets, Dividend, and Risks

Pfizer Stock (PFE) Before Market Open Dec. 15, 2025: Key News, 2026 Guidance Call, Analyst Targets, Dividend, and Risks

Pfizer closed Friday at $25.85, near the upper end of its 52-week range. Investors are focused on the company’s analyst call Tuesday, where management will issue 2026 financial guidance. Pfizer’s dividend yield remains in the mid-6% range, while short interest stands at about 2.45% of float. Policy uncertainty for COVID vaccines and efforts to grow oncology and cardiometabolic revenue remain in focus.
14 December 2025
··
Pfizer Stock (PFE) News and Forecast for Dec. 14, 2025: Dividend, Obesity Deal, Oncology Catalysts, and What Analysts Expect Next

Pfizer Stock (PFE) News and Forecast for Dec. 14, 2025: Dividend, Obesity Deal, Oncology Catalysts, and What Analysts Expect Next

Pfizer shares closed at $25.85 Friday, Dec. 12, with volume near 50.8 million. The company declared a $0.43 per share dividend for Q1 2026, marking its 349th consecutive payout. New trial data showed Tukysa cut risk of progression or death in HER2+ metastatic breast cancer by about 36%. Investors remain focused on dividend sustainability and pipeline developments.
14 December 2025
··
Pfizer Stock (PFE) Outlook: This Week’s Key Headlines, Dividend Update, and What to Watch Ahead of 2026 Guidance (Updated Dec. 14, 2025)

Pfizer Stock (PFE) Outlook: This Week’s Key Headlines, Dividend Update, and What to Watch Ahead of 2026 Guidance (Updated Dec. 14, 2025)

Pfizer shares closed at $25.85, below their 52-week high but above the low. The company declared a $0.43 first-quarter 2026 dividend, its 349th consecutive payout. Investors await Tuesday’s analyst call, where management will issue full-year 2026 guidance. A new obesity drug licensing deal with YaoPharma was also announced.
14 December 2025
··
Healthcare & Pharma Giants US Stocks: Week Ahead Outlook After Eli Lilly’s Retatrutide, CVS Guidance, Pfizer’s Obesity Deal, and J&J’s Talc Verdict (Updated Dec. 14, 2025)

Healthcare & Pharma Giants US Stocks: Week Ahead Outlook After Eli Lilly’s Retatrutide, CVS Guidance, Pfizer’s Obesity Deal, and J&J’s Talc Verdict (Updated Dec. 14, 2025)

Eli Lilly reported late-stage trial success for its obesity drug retatrutide, with patients losing 28.7% of body weight over 68 weeks. Pfizer re-entered the obesity drug market through a $150 million licensing deal with Yao Pharma. The FDA moved to accelerate review of Lilly’s oral GLP-1 pill, orforglipron, possibly advancing a decision to March. The Fed cut rates by 25 basis points and signaled new Treasury purchases.
14 December 2025
······
Pfizer Stock (PFE) Outlook: GLP‑1 Weight‑Loss Deal, Tukysa Trial Win, Dividend Declared — and the Big Catalyst Next Week (Updated Dec. 12, 2025)

Pfizer Stock (PFE) Outlook: GLP‑1 Weight‑Loss Deal, Tukysa Trial Win, Dividend Declared — and the Big Catalyst Next Week (Updated Dec. 12, 2025)

Pfizer shares closed at $25.85 Friday, up 0.19%, after announcing a global obesity drug deal with YaoPharma and reporting positive Phase 3 data for breast cancer drug Tukysa. The company also highlighted strong hemophilia trial results and declared a $0.43 per share dividend, payable March 6, 2026. Trading volume reached about 23 million shares.
13 December 2025
···
Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA “Black Box” Headline, Analyst Forecasts — What to Know Before the Next Market Open

Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA “Black Box” Headline, Analyst Forecasts — What to Know Before the Next Market Open

Pfizer shares closed at $25.85 on Dec. 12, 2025, up 0.19%, and edged to $25.89 in after-hours trading. The company declared a $0.43 per-share dividend for Q1 2026. Trading volume reached 50.8 million shares during the session, with 1.56 million shares after hours. U.S. markets remain closed until Monday, Dec. 15.
13 December 2025
··
Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA Vaccine Warning Headlines, and What to Watch Before the Next Market Open

Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA Vaccine Warning Headlines, and What to Watch Before the Next Market Open

Pfizer shares closed up 0.19% at $25.85 Friday, with after-hours trading lifting the stock slightly to $25.88. The company declared a $0.43 per-share quarterly dividend, payable March 6, 2026. Investors also reacted to reports of a possible FDA “black box” warning for COVID-19 vaccines and new late-stage data on breast-cancer drug Tukysa.
13 December 2025
··
Pfizer (PFE) Stock Outlook After the November 21 FDA Win: Obesity Deals, Cost Cuts and a 6.7% Dividend Yield

Pfizer (PFE) Stock Outlook After the November 21 FDA Win: Obesity Deals, Cost Cuts and a 6.7% Dividend Yield

Pfizer shares traded at $25.66 on December 11, 2025, following an FDA approval for PADCEV plus Keytruda in bladder cancer and a new GLP‑1 weight-loss deal. The company declared a $0.43 per-share dividend for Q4, marking its 348th consecutive quarterly payout. Pfizer’s annualized yield stands at about 6.7%. Consensus 2025 EPS is $3.1–$3.2, giving a forward P/E near 8.
11 December 2025
·
Pfizer (PFE) Stock Premarket Today, Dec. 11, 2025: Marshall Wace Exit, Obesity Drug Deals and 2026 Guidance in Focus

Pfizer (PFE) Stock Premarket Today, Dec. 11, 2025: Marshall Wace Exit, Obesity Drug Deals and 2026 Guidance in Focus

Pfizer shares traded near $25.78 early Thursday, flat from Wednesday’s close, after hedge fund Marshall Wace disclosed a 96.8% reduction in its stake. The stock remains over 50% below its December 2021 high. Pfizer’s 52-week range is $20.92 to $27.69, with a market cap near $147 billion and a dividend yield around 6.7%.
11 December 2025
··
Pfizer Stock Today: Obesity Deal, Cancer Breakthroughs and Job Cuts Shape PFE’s 2025 Outlook

Pfizer Stock Today: Obesity Deal, Cancer Breakthroughs and Job Cuts Shape PFE’s 2025 Outlook

Pfizer shares traded near $25.5 on December 10, up less than 1% but still over 50% below their 2021 peak. The company announced a $2.1 billion obesity-drug partnership with China’s YaoPharma, reported Phase 3 wins for TUKYSA and HYMPAVZI, and confirmed new job cuts in Switzerland. Dividend yield stands near 6.7%. Pfizer reaffirmed 2025 adjusted EPS guidance at $3.00–$3.15.
10 December 2025
··
Pfizer (PFE) Stock After Hours on December 9, 2025: Obesity Pill Deal, RSV Questions, and What to Watch Before the Opening Bell

Pfizer (PFE) Stock After Hours on December 9, 2025: Obesity Pill Deal, RSV Questions, and What to Watch Before the Opening Bell

Pfizer shares closed down 1.7% at $25.33 on December 9, 2025, with volume below average. After hours, the stock edged up to $25.40 as investors reacted to Pfizer’s new global licensing deal with YaoPharma for an early-stage oral obesity drug. The agreement includes a $150 million upfront payment and potential milestones up to $2.1 billion.
10 December 2025
····
Pfizer (PFE) Stock Today: Hemophilia Breakthrough, Metsera Deal and AI Cost Cuts – Price, Forecast and News for December 8, 2025

Pfizer (PFE) Stock Today: Hemophilia Breakthrough, Metsera Deal and AI Cost Cuts – Price, Forecast and News for December 8, 2025

Pfizer shares traded near $26 on December 8, 2025, with a market cap around $148 billion and a dividend yield of 6.6–7%. The stock remains down about 36% over five years and over 50% below its December 2021 peak. New Phase 3 hemophilia data, an obesity-drug acquisition, and AI-driven cost cuts drew investor attention. Year-to-date total return is flat to slightly positive, depending on dividend inclusion.
8 December 2025
···
Pfizer (PFE) Stock on December 6, 2025: Metsera Deal, 2025 Guidance and What Wall Street Expects Next

Pfizer (PFE) Stock on December 6, 2025: Metsera Deal, 2025 Guidance and What Wall Street Expects Next

Pfizer shares closed at $26.03 on December 5, 2025, up 1.28% and 24% above April’s low. The stock yields about 6.6% with an annualized dividend of $1.72 per share and has paid 347 consecutive quarterly dividends. Pfizer’s Q3 revenue fell 6% to $16.65 billion, but adjusted EPS beat expectations at $0.87. The stock trades at 8–9x forward earnings, below the market average.
6 December 2025
···
Pfizer (PFE) Stock Today: Price, Metsera Obesity Deal, 2025–2026 Forecast and Key Risks

Pfizer (PFE) Stock Today: Price, Metsera Obesity Deal, 2025–2026 Forecast and Key Risks

Pfizer shares traded near $26 late December 5, up about 1%, with a market cap of $146 billion and a dividend yield close to 7%. New analyst coverage flagged tighter FDA COVID vaccine rules and looming patent expirations for key drugs as risks. The stock remains 36% below its five-year level despite recent gains. Investors await updated 2026 guidance and details on a major obesity-drug acquisition.
5 December 2025
···
Pfizer Stock (PFE) Today – Price, Metsera Obesity Bet, RSV Vaccine Tailwinds and 2026 Forecast (3 December 2025)

Pfizer Stock (PFE) Today – Price, Metsera Obesity Bet, RSV Vaccine Tailwinds and 2026 Forecast (3 December 2025)

Pfizer shares traded at $25.60 late December 3, 2025, near the midpoint of their 52-week range and well below 2021 highs. The stock yields about 6.5–7% and trades at 8–9x forward earnings after a $10 billion obesity-drug deal. Technical analysis points to support near $24.95 and resistance around $26.10. Market capitalization stands near $144 billion.
3 December 2025
···
Pfizer Stock Price Today (PFE): TrumpRx Drug Deal, $10B Metsera Buyout and 2026 Forecast

Pfizer Stock Price Today (PFE): TrumpRx Drug Deal, $10B Metsera Buyout and 2026 Forecast

Pfizer closed at $25.74 on November 28, with a market cap near $146 billion, down about 50% from its 2021–22 COVID peak. Q3 2025 revenue fell 6–7% to $16.7 billion as COVID sales declined, but adjusted EPS beat at $0.87. The company raised 2025 EPS guidance to $3.00–$3.15 and reaffirmed revenue targets. On September 30, Pfizer agreed to cut Medicaid drug prices in exchange for U.S. export tariff relief.
30 November 2025
··
1 … 4 5 6 7 8 … 10

Stock Market Today

  • Unilever Shifts Focus to Beauty and Wellness, Merges Foods Unit with McCormick
    April 11, 2026, 2:05 AM EDT. Unilever is restructuring by merging its Foods business, including Knorr and Hellmann's, with McCormick to form a global flavour group. The move signals a strategic pivot towards beauty, wellbeing, personal care, and home care as core areas. Unilever also acquired the US supplements brand Grüns to boost its health and wellness portfolio. Shares in Unilever (LSE:ULVR) show modest gains recently amid larger declines over the past year. The deal values the Foods unit at a 3.6x EV/Sales multiple. Proceeds from the transaction will fund debt reduction and a €6 billion share buyback between 2026-2029. Investors face a shift from a diversified pantry portfolio to a concentrated premium consumer business and a continued stake in a competitive global flavour group. Execution and market valuation remain key concerns as Unilever sharpens its focus.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 11.04.2026

11 April 2026
LIVEMarkets rolling coverageStarted: April 11, 2026, 12:00 AM EDTUpdated: April 11, 2026, 2:18 AM EDT Unilever Shifts Focus to Beauty and Wellness, Merges Foods Unit with McCormick April 11, 2026, 2:05 AM EDT. Unilever is restructuring by merging its Foods business, including Knorr and Hellmann's, with McCormick to form a global flavour group. The move signals a strategic pivot towards **beauty, wellbeing, personal care, and home care** as core areas. Unilever also acquired the US supplements brand Grüns to boost its **health and wellness** portfolio. Shares in Unilever (LSE:ULVR) show modest gains recently amid larger declines over the past year.
UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

10 April 2026
London’s FTSE 100 rose 0.38% to 10,644.28 late Friday morning as investors awaited U.S.-Iran talks in Pakistan. Brent crude climbed 1% to $96.83 a barrel, while sterling eased but was on track for its biggest weekly gain since January. The FTSE 250 gained 0.79%. Britain’s 10-year gilt yield stood at 4.807%.
US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

10 April 2026
Dow e-minis slipped 0.15% before Friday’s open, with S&P 500 and Nasdaq 100 futures each down 0.08% as traders awaited March CPI data and watched U.S.-Iran tensions. Economists expect headline CPI to rise 0.9% for March and 3.3% year-on-year. Weekly jobless claims increased to 219,000. Brent crude traded near $97 a barrel, while shipping through the Strait of Hormuz remained well below normal.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 10.04.2026

10 April 2026
LIVEMarkets rolling coverageStarted: April 10, 2026, 12:00 AM EDTUpdated: April 10, 2026, 11:59 PM EDT Orora ASX:ORA Faces Earnings Reset After Saverglass Impact and Middle East Disruptions April 10, 2026, 11:59 PM EDT. Orora (ASX:ORA) shares plunged over 8% in one day following a guidance update that revealed an earnings reset at its Saverglass unit due to Middle East supply chain disruptions and a shutdown at the Ras Al Khaimah glass plant. Despite a sharp short-term loss, Orora's 90-day share price rise exceeds 33%, contrasting a longer-term 10.58% annual total shareholder return decline amid ongoing sector pressures. Trading at A$1.49,
Go toTop